Renall cell carcinoma Kidney cancer
Conditions
Interventions
In total 40 patients will be treated for RCC using SBRT. 
 
For 15 patients, additional breath-hold CBCT scans will be made during SBRT to investigate the intra- and inter-fraction uncertainty in breath-hold positions as well as assessing the feasibility of us
Subsequently, 25 patients will be treated using the new motion management technique developed using the extra imaging data obtained from the first cohort of patients. It is hypothesized that either br
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidenceNo metastatic lesions Patients must be 18 years or olderAbility to understand the requirements of the study and to give written informed consent, as determined by the treating physician.Written informed consent
Exclusion criteria
Exclusion criteria: Previous high-dose radiotherapy in the region of the kidney
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary aim of this project is to minimize treatment margins, thereby reducing the treated target volume, to optimally preserve renal function, while ensuring adequate tumor coverage as well as adhering to dose constraints of OARs. Primary endpoint of this study is the reduction of renal dose, in specific the volume receiving 50% of the prescribed dose (V50%). | — |
Secondary
| Measure | Time frame |
|---|---|
| To achieve the primary objective, we aim to: Characterize intra- and inter-fraction motion to improve motion management and enable margin reduction Evaluate whether surface guidance in combination with CBCT can be an adequate surrogate marker for renal position during treatment to evaluate the possibility of treatment in breath-hold position Evaluate whether surface guidance can be an adequate surrogate marker for renal motion during treatment to evaluate the possibility of treatment using gating Additionally, we aim to: Evaluate the current treatment, including the benefit of online adaptive radiotherapy Assess feasibility of safely shifting from 5×8 Gy to 3×14 Gy or 1×26 Gy schedules to improve efficiency, patient convenience, and clinical outcomes Explore photon-counting CT (PCCT) for improved treatment response assessment. Assess clinical outcomes, with a focus on renal function, acute side effects, and local control | — |
Countries
Netherlands
Contacts
Public ContactE.A.M. Froklage
Erasmus MC, Universitair Medisch Centrum Rotterdam
Outcome results
None listed